An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Roche

Status: Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01535729

ML23023

Details and patient eligibility

About

This prospective observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in elderly patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Data of patients treated with Tarceva in routine clinical practice will be collected for 1 year.

Enrollment: 465 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, > 65 years of age
• Locally advanced or metastatic non-small cell lung cancer (Stage IIIb or IV)
• Failure of at least one prior standard platinum-based chemotherapy

Exclusion criteria

• Age < 65 years

Trial design

465 participants in 1 patient group

Cohort